Condition
Torsades de Pointes
Total Trials
5
Recruiting
2
Active
2
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
66.7%
-19.9% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
67% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
P 1 (1)
Trial Status
Recruiting2
Completed2
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07014735Not ApplicableTerminated
Effect of Hyperglycaemia and Moxifloxacin on QTc Interval in T2DM
NCT07374263Recruiting
Do QT-Prolonging Drugs Cause Major Adverse Cardiac Events in Hospitalized Adults?
NCT05521451Recruiting
Clinical Cohort Study - TRUST
NCT04000542Not ApplicableCompleted
Pharmacist Use of ECG to Inform Drug Therapy Decisions for Patients Receiving QT Prolonging Medications
NCT00839891Phase 1CompletedPrimary
A Study to Evaluate How VI-0521 Affect Cardiac Repolarization in Healthy Male and Female Volunteers
Showing all 5 trials